Tuesday June 17, 2014 0 commentsBROOMFIELD - MicroBiome Therapeutics LLC today reported a recently published scientific study shows the diabetes drug, metformin, alters the bacterial populations in the gut in favor of a bacterial species that exerts specific cellular and immunological effects, resulting in improved glycemic control.
The company said it is the first study to demonstrate a link between metformin and changes in the gut microbiota and provides insights into the possible mechanism of action of NM504 and NM505, MBT's lead microbiome modulators in clinical development for diabetes and prediabetes.
Metformin is a first-line treatment for type 2 diabetes and the seventh most prescribed drug in the U.S., MBT said.
The new study was recently published in the journal Gut and showed metformin treatment significantly improved the glycemic profile of mice that became obese after receiving a high-fat diet.
"This elegant study, the first to demonstrate a link between the anti-diabetic efficacy of metformin and changes in the gut microbiome, may offer insights into why the pilot study testing our microbiome modulator - NM504 - in combination with metformin produced an unexpectedly large drop in blood glucose levels beyond what had been achieved with metformin alone," said Steve Orndorff, MBT CEO.